HIV prevention cost-effectiveness: a systematic review.

PubWeight™: 1.58‹?› | Rank: Top 4%

🔗 View Article (PMC 2779507)

Published in BMC Public Health on November 18, 2009


Omar Galárraga1, M Arantxa Colchero, Richard G Wamai, Stefano M Bertozzi

Author Affiliations

1: Center for Evaluation Research and Surveys, Mexican School of Public Health/National Institute of Public Health (INSP), Av. Universidad 655, Cuernavaca, Mexico CP 62508.

Articles citing this

Voluntary medical male circumcision: modeling the impact and cost of expanding male circumcision for HIV prevention in eastern and southern Africa. PLoS Med (2011) 7.56

Male circumcision for HIV prevention: current evidence and implementation in sub-Saharan Africa. J Int AIDS Soc (2011) 1.42

A 'snip' in time: what is the best age to circumcise? BMC Pediatr (2012) 1.36

Infectious co-factors in HIV-1 transmission herpes simplex virus type-2 and HIV-1: new insights and interventions. Curr HIV Res (2012) 1.33

Economic evaluations of adult male circumcision for prevention of heterosexual acquisition of HIV in men in sub-Saharan Africa: a systematic review. PLoS One (2010) 1.28

Is there scope for cost savings and efficiency gains in HIV services? A systematic review of the evidence from low- and middle-income countries. Bull World Health Organ (2014) 1.19

Integrated HIV testing, malaria, and diarrhea prevention campaign in Kenya: modeled health impact and cost-effectiveness. PLoS One (2012) 1.18

Cost-effectiveness of HIV prevention interventions in Andhra Pradesh state of India. BMC Health Serv Res (2010) 0.97

Cost-effectiveness of antiretroviral therapy for prevention. Curr HIV Res (2011) 0.95

Cost-effectiveness of school support for orphan girls to prevent HIV infection in Zimbabwe. Prev Sci (2013) 0.95

Willingness-to-accept reductions in HIV risks: conditional economic incentives in Mexico. Eur J Health Econ (2013) 0.95

Review: a critical evaluation of arguments opposing male circumcision for HIV prevention in developed countries. AIDS Care (2012) 0.93

Economic Evaluation in Global Perspective: A Bibliometric Analysis of the Recent Literature. Health Econ (2016) 0.92

Optimal allocation of resources in female sex worker targeted HIV prevention interventions: model insights from Avahan in South India. PLoS One (2014) 0.87

Paying for prevention: challenges to health insurance coverage for biomedical HIV prevention in the United States. Am J Law Med (2012) 0.85

Harnessing the prevention benefits of antiretroviral therapy to address HIV and tuberculosis. Curr HIV Res (2011) 0.84

Spending of HIV resources in Asia and Eastern Europe: systematic review reveals the need to shift funding allocations towards priority populations. J Int AIDS Soc (2014) 0.81

Community mobilisation and empowerment interventions as part of HIV prevention for female sex workers in Southern India: a cost-effectiveness analysis. PLoS One (2014) 0.81

A Cost-Effectiveness Analysis of a Home-Based HIV Counselling and Testing Intervention versus the Standard (Facility Based) HIV Testing Strategy in Rural South Africa. PLoS One (2015) 0.80

The OptAIDS project: towards global halting of HIV/AIDS. BMC Public Health (2009) 0.79

HIV Prevalence and Antenatal Care Attendance among Pregnant Women in a Large Home-Based HIV Counseling and Testing Program in Western Kenya. PLoS One (2016) 0.77

Policy makers, the international community and the population in the prevention and treatment of diseases: case study on HIV/AIDS. Health Econ Rev (2017) 0.75

[Cost-benefit analysis: HIV/AIDS prevention in migrants in Central America]. Salud Publica Mex (2013) 0.75

Implementation and Operational Research: A Time-Motion Analysis of HIV Transmission Prevention Counseling and Antiretroviral Adherence Messages in Western Kenya. J Acquir Immune Defic Syndr (2015) 0.75

A quarter of a century with AIDS. Open AIDS J (2011) 0.75

The dollars and sense of economic incentives to modify HIV-related behaviours. J Int AIDS Soc (2015) 0.75

Cost-effectiveness analysis of malaria interventions using disability adjusted life years: a systematic review. Cost Eff Resour Alloc (2017) 0.75

HIV prevention resources: time to move toward affordability. Lancet HIV (2017) 0.75

Articles cited by this

Impact of improved treatment of sexually transmitted diseases on HIV infection in rural Tanzania: randomised controlled trial. Lancet (1995) 21.03

Efficacy of voluntary HIV-1 counselling and testing in individuals and couples in Kenya, Tanzania, and Trinidad: a randomised trial. The Voluntary HIV-1 Counseling and Testing Efficacy Study Group. Lancet (2000) 10.81

Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis (2005) 10.20

Effects of HIV counseling and testing on sexual risk behavior: a meta-analytic review of published research, 1985-1997. Am J Public Health (1999) 8.91

Behavioural strategies to reduce HIV transmission: how to make them work better. Lancet (2008) 7.42

Diaphragm and lubricant gel for prevention of HIV acquisition in southern African women: a randomised controlled trial. Lancet (2007) 7.22

Narrative review: antiretroviral therapy to prevent the sexual transmission of HIV-1. Ann Intern Med (2007) 7.14

Conditional cash transfers for improving uptake of health interventions in low- and middle-income countries: a systematic review. JAMA (2007) 7.10

Cost-effectiveness of HIV/AIDS interventions in Africa: a systematic review of the evidence. Lancet (2002) 6.47

Structural approaches to HIV prevention. Lancet (2008) 6.41

HIV prevention before HAART in sub-Saharan Africa. Lancet (2002) 5.55

Perspectives on the basic reproductive ratio. J R Soc Interface (2005) 5.34

HIV voluntary counseling and testing and behavioral risk reduction in developing countries: a meta-analysis, 1990--2005. AIDS Behav (2007) 4.61

Cost-effectiveness of male circumcision for HIV prevention in a South African setting. PLoS Med (2006) 4.34

Sex and HIV education programs: their impact on sexual behaviors of young people throughout the world. J Adolesc Health (2007) 4.32

Public health. Reassessing HIV prevention. Science (2008) 4.06

Development of WHO guidelines on generalized cost-effectiveness analysis. Health Econ (2000) 3.95

Cost effectiveness analysis of strategies to combat HIV/AIDS in developing countries. BMJ (2005) 3.83

A randomized, community trial of intensive sexually transmitted disease control for AIDS prevention, Rakai, Uganda. AIDS (1998) 3.54

The Demand for, and Impact of, Learning HIV Status. Am Econ Rev (2008) 3.25

Coming to terms with complexity: a call to action for HIV prevention. Lancet (2008) 3.15

The Global HIV/AIDS Vaccine Enterprise: scientific strategic plan. PLoS Med (2005) 2.95

Herpes simplex virus type 2 infection increases HIV incidence: a prospective study in rural Tanzania. AIDS (2002) 2.93

Preventing HIV/AIDS in young people. A systematic review of the evidence from developing countries. Introduction and rationale. World Health Organ Tech Rep Ser (2006) 2.82

The global impact of scaling up HIV/AIDS prevention programs in low- and middle-income countries. Science (2006) 2.76

Biomedical interventions to prevent HIV infection: evidence, challenges, and way forward. Lancet (2008) 2.75

Uptake of workplace HIV counselling and testing: a cluster-randomised trial in Zimbabwe. PLoS Med (2006) 2.71

Impact and process evaluation of integrated community and clinic-based HIV-1 control: a cluster-randomised trial in eastern Zimbabwe. PLoS Med (2007) 2.56

HIV prevention costs and program scale: data from the PANCEA project in five low and middle-income countries. BMC Health Serv Res (2007) 2.55

Male circumcision for HIV prevention in sub-Saharan Africa: who, what and when? AIDS (2008) 2.54

Global epidemiology of sexually transmitted diseases. Lancet (1998) 2.54

The value of contraception to prevent perinatal HIV transmission. Sex Transm Dis (2006) 2.49

Antiretroviral treatment in resource-poor settings: clinical research priorities. Lancet (2002) 2.36

Making HIV prevention programmes work. Lancet (2008) 2.22

The impact of male circumcision on HIV incidence and cost per infection prevented: a stochastic simulation model from Rakai, Uganda. AIDS (2007) 2.19

Combination HIV prevention. Lancet (2008) 2.10

Population-based interventions for reducing sexually transmitted infections, including HIV infection. Cochrane Database Syst Rev (2004) 2.09

Does scale matter? The costs of HIV-prevention interventions for commercial sex workers in India. Bull World Health Organ (2005) 1.99

Biomedical HIV prevention--and social science. Lancet (2007) 1.95

The effectiveness of adolescent reproductive health interventions in developing countries: a review of the evidence. J Adolesc Health (2003) 1.89

Cost and cost-effectiveness of HIV/AIDS prevention strategies in developing countries: is there an evidence base? Health Policy Plan (2003) 1.82

Squaring the circle: AIDS, poverty, and human development. PLoS Med (2007) 1.77

The effectiveness of sex education and HIV education interventions in schools in developing countries. World Health Organ Tech Rep Ser (2006) 1.67

Modelling the impact and cost-effectiveness of the HIV intervention programme amongst commercial sex workers in Ahmedabad, Gujarat, India. BMC Public Health (2007) 1.57

The impact of an AIDS vaccine in developing countries: a new model and initial results. Health Aff (Millwood) (2007) 1.48

Treating curable sexually transmitted infections to prevent HIV in Africa: still an effective control strategy? J Acquir Immune Defic Syndr (2008) 1.48

The MEMA kwa Vijana project: design of a community randomised trial of an innovative adolescent sexual health intervention in rural Tanzania. Contemp Clin Trials (2005) 1.39

Antiretroviral treatment in resource-poor settings: the Brazilian experience. AIDS (2004) 1.39

Costs of measures to control tuberculosis/HIV in public primary care facilities in Cape Town, South Africa. Bull World Health Organ (2006) 1.32

The economics of scaling up: cost estimation for HIV/AIDS interventions. AIDS (2008) 1.28

The economics of HIV/AIDS in low-income countries: the case for prevention. J Econ Perspect (2006) 1.25

Failure of the Merck HIV vaccine: an uncertain step forward. Lancet (2008) 1.21

Cost-effectiveness of HIV rescreening during late pregnancy to prevent mother-to-child HIV transmission in South Africa and other resource-limited settings. J Acquir Immune Defic Syndr (2006) 1.21

A cost function for HIV prevention services: is there a 'u' - shape? Cost Eff Resour Alloc (2007) 1.18

The cost-effectiveness of expanding harm reduction activities for injecting drug users in Odessa, Ukraine. Sex Transm Dis (2006) 1.16

Are targeted HIV prevention activities cost-effective in high prevalence settings? Results from a sexually transmitted infection treatment project for sex workers in Johannesburg, South Africa. Sex Transm Dis (2006) 1.14

The cost-effectiveness of a competitive voucher scheme to reduce sexually transmitted infections in high-risk groups in Nicaragua. Health Policy Plan (2005) 1.14

Advance market commitments for vaccines against neglected diseases: estimating costs and effectiveness. Health Econ (2007) 1.11

Antiretroviral therapy and HIV prevention in India: modeling costs and consequences of policy options. Sex Transm Dis (2006) 1.10

Cost-effectiveness of models for prevention of vertical HIV transmission - voluntary counseling and testing and choices of drug regimen. Cost Eff Resour Alloc (2005) 1.09

Cost effectiveness of couple counselling to enhance infant HIV-1 prevention. Int J STD AIDS (2008) 1.04

Randomised trials of HIV prevention. Lancet (2007) 1.02

Low effectiveness of syndromic treatment services for curable sexually transmitted infections in rural South Africa. Sex Transm Infect (2008) 1.01

How can we calculate the "E" in "CEA"? AIDS (2008) 0.99

Country-wide distribution of the nitrile female condom (FC2) in Brazil and South Africa: a cost-effectiveness analysis. AIDS (2006) 0.94

Scientific and policy challenges to development of an AIDS vaccine. Lancet (2007) 0.94

Potential cost-effectiveness of maternal and infant antiretroviral interventions to prevent mother-to-child transmission during breast-feeding. J Acquir Immune Defic Syndr (2005) 0.93

Cost-effectiveness of environmental-structural communication interventions for HIV prevention in the female sex industry in the Dominican Republic. J Health Commun (2006) 0.91

HIV prevention programs of nongovernmental organizations in Latin America and the Caribbean: the Global AIDS Intervention Network project. Rev Panam Salud Publica (2005) 0.85

[A comparison of three screening strategies for prevention of perinatal HIV infection in Colombia: a decision analysis model]. Rev Panam Salud Publica (2008) 0.85

The cost-effectiveness of treating male trichomoniasis to avert HIV transmission in men seeking sexually transmitted disease care in Malawi. J Acquir Immune Defic Syndr (2006) 0.82

Warning is sent to AIDS vaccine volunteers. AIDS Read (2007) 0.77

Betting on HIV prevention. Lancet (2006) 0.77

Articles by these authors

Severe respiratory disease concurrent with the circulation of H1N1 influenza. N Engl J Med (2009) 8.99

HIV prevention transformed: the new prevention research agenda. Lancet (2011) 4.23

Public health. Reassessing HIV prevention. Science (2008) 4.06

High risk of HIV in non-brothel based female sex workers in India. BMC Public Health (2005) 3.58

Sex behaviour of men who have sex with men and risk of HIV in Andhra Pradesh, India. AIDS (2005) 3.35

Achieving the WHO/UNAIDS antiretroviral treatment 3 by 5 goal: what will it cost? Lancet (2004) 3.14

Estimated numbers of men and women infected with HIV/AIDS in Tijuana, Mexico. J Urban Health (2006) 3.04

Economic impact of antiretroviral therapy prescription decisions in the context of rapid scaling-up of access to treatment: lessons from Mexico. AIDS (2006) 2.87

HIV prevention costs and program scale: data from the PANCEA project in five low and middle-income countries. BMC Health Serv Res (2007) 2.55

Current priorities in health research funding and lack of impact on the number of child deaths per year. Am J Public Health (2006) 2.44

Combination HIV prevention. Lancet (2008) 2.10

Optimizing resource allocation for HIV/AIDS prevention programmes: an analytical framework. AIDS (2008) 1.87

Demography and sex work characteristics of female sex workers in India. BMC Int Health Hum Rights (2006) 1.76

How the Avahan HIV prevention program transitioned from the Gates Foundation to the government of India. Health Aff (Millwood) (2013) 1.50

Modeling the economic net benefit of a potential vaccination program against ocular infection with Chlamydia trachomatis. Vaccine (2004) 1.47

Estimating the burden and economic impact of trachomatous visual loss. Ophthalmic Epidemiol (2003) 1.43

A 'snip' in time: what is the best age to circumcise? BMC Pediatr (2012) 1.36

Emergency contraception use is correlated with increased condom use among adolescents: results from Mexico. J Adolesc Health (2004) 1.33

Evaluation of large-scale combination HIV prevention programs: essential issues. J Acquir Immune Defic Syndr (2011) 1.32

Adaptive vaccination strategies to mitigate pandemic influenza: Mexico as a case study. PLoS One (2009) 1.24

The costs, benefits, and cost-effectiveness of interventions to reduce maternal morbidity and mortality in Mexico. PLoS One (2007) 1.18

Variations in prenatal care quality for the rural poor in Mexico. Health Aff (Millwood) (2007) 1.17

Community-based prevention leads to an increase in condom use and a reduction in sexually transmitted infections (STIs) among men who have sex with men (MSM) and female sex workers (FSW): the Frontiers Prevention Project (FPP) evaluation results. BMC Public Health (2010) 1.15

Is the HIV epidemic stable among MSM in Mexico? HIV prevalence and risk behavior results from a nationally representative survey among men who have sex with men. PLoS One (2013) 1.14

Risk behaviors of 15-21 year olds in Mexico lead to a high prevalence of sexually transmitted infections: results of a survey in disadvantaged urban areas. BMC Public Health (2006) 1.13

HIV prevention in Mexican schools: prospective randomised evaluation of intervention. BMJ (2006) 1.09

Forecast of demand for antiretroviral drugs in low and middle-income countries: 2007-2008. AIDS (2007) 1.09

Is male circumcision as good as the HIV vaccine we've been waiting for? Futur HIV Ther (2008) 1.04

Costing of scaling up HIV/AIDS treatment in Mexico. Salud Publica Mex (2008) 1.02

How much attention is needed towards men who sell sex to men for HIV prevention in India? BMC Public Health (2006) 1.02

HIV testing among female sex workers in Andhra Pradesh, India. AIDS (2005) 1.01

Correlates of condom use in a sample of MSM in Ecuador. BMC Public Health (2006) 0.99

Cost-effectiveness of introducing a rotavirus vaccine in developing countries: the case of Mexico. BMC Infect Dis (2008) 0.96

High prevalence of obesity among the poor in Mexico. JAMA (2004) 0.95

Willingness-to-accept reductions in HIV risks: conditional economic incentives in Mexico. Eur J Health Econ (2013) 0.95

Review: a critical evaluation of arguments opposing male circumcision for HIV prevention in developed countries. AIDS Care (2012) 0.93

Awareness, acceptability and uptake of human papilloma virus vaccine among Cameroonian school-attending female adolescents. J Community Health (2012) 0.92

Cost-effectiveness of implementation methods for ELISA serology testing of Trypanosoma cruzi in California blood banks. Am J Trop Med Hyg (2008) 0.91

Evaluation of HIV prevention programmes: the case of Avahan. Sex Transm Infect (2010) 0.89

Cost-effectiveness of strategies to reduce mother-to-child HIV transmission in Mexico, a low-prevalence setting. Health Policy Plan (2003) 0.88

Optimizing HIV treatment programs. Curr Opin HIV AIDS (2010) 0.87

Access to condoms for female sex workers in Andhra Pradesh. Natl Med J India (2007) 0.86

Cost of AIDS care in Mexico: what are its main individual predictors? Arch Med Res (2005) 0.84

Can cost studies improve the performance of donor-financed HIV treatment? AIDS (2011) 0.81

Herpes simplex virus type 2 among Mexican high school adolescents: prevalence and association with community characteristics. Arch Med Res (2007) 0.80

[A novel school-based strategy for the prevention of HIV/AIDS, sexually transmitted disease (STDs), and teen pregnancies]. Salud Publica Mex (2006) 0.80

[Facing the HIV/AIDS epidemic in Mexico: the response of the health sector]. Rev Invest Clin (2004) 0.79

Improving enrollment and utilization of the Oportunidades program in Mexico could increase its effectiveness. J Nutr (2008) 0.79

The economic impacts of HIV/AIDS on households and economies. AIDS (2008) 0.79

Stakeholders' opinions and expectations of the Global Fund and their potential economic implications. AIDS (2008) 0.78

A predictive model for the utilization of curative ambulatory health services in Mexico. Salud Publica Mex (2008) 0.78

[Influenza vaccination in the elderly population in Mexico: economic considerations]. Salud Publica Mex (2005) 0.76

Improving access to treatment for HIV in sub-Saharan Africa. BMJ (2010) 0.75

Scaling up HAART in Mexico. Response to Volkow et al. AIDS (2007) 0.75

[Cost-effectiveness of breast cancer screening policies in Mexico]. Salud Publica Mex (2009) 0.75

[Mixed design for the evaluation of the Mesoamerica Health 2015 initiative]. Salud Publica Mex (2011) 0.75

Post-emergency: providing effective, sustainable, life-long care to everyone with AIDS. Indian J Med Res (2006) 0.75

Cost-effectiveness of alternative strategies to prevent trachomatous blindness. Expert Rev Pharmacoecon Outcomes Res (2002) 0.75

Informing scale-up and resource allocation: the use of economic analysis. AIDS (2008) 0.75

[The health gap in Mexico, measured through child mortality]. Salud Publica Mex (2003) 0.75

Combining evidence for access to and benefits from antiretroviral treatment to inform planning. AIDS (2008) 0.75

Re: This special issue of AIDS--a mix of recent economic analyses and commentary on how best to distill economic insights to improve HIV/AIDS policies and programmes. AIDS (2008) 0.75